drugset / Trial / NCT00003335

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

NCT00003335

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: This phase II trial is studying allogeneic umbilical cord blood transplantation to see how well it works when given with chemotherapy or radiation therapy in treating patients with high-risk hematologic cancer.

Timeline

Start
1998-01
Primary completion
2007-11
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic Intravenous
Background Busulfan Small molecule Oral
Background Cyclosporine Peptide
Background Melphalan Small molecule Intravenous
Background Methylprednisolone Other / unclassified Intravenous